What semaglutide is, in plain English
Semaglutide is a prescription medicine in a class called GLP-1 receptor agonists. It copies a natural gut hormone that helps control blood sugar and appetite. In the United States it is sold under brand names as a once-weekly injection and as daily tablets. Approved uses differ by product, and every version is prescription only.
Most people arrive here for one of three reasons. They were just handed a prescription. They are weighing up an online program. Or they want to know what one month actually costs when nobody else is paying. This guide covers what the drug does, what US labeling allows, the risks worth taking seriously, and the parts of the price that shift from program to program. For the formal wording, the patient-facing summary at MedlinePlus drug information is a good companion to the manufacturer label.
How the medicine works inside the body
Your gut releases GLP-1 after you eat. That hormone tells the pancreas to release insulin, tells the liver to ease off sugar production, slows how fast the stomach empties, and signals the brain that you have had enough. Natural GLP-1 breaks down within minutes. This drug is built to last far longer, which is why the injectable form is taken weekly rather than daily.
Three of those effects matter most to patients. Insulin release is glucose dependent, meaning it ramps up when blood sugar is high and quiets down when it is not. On its own, that keeps the risk of dangerously low blood sugar relatively low, though the picture changes when other diabetes drugs are added. Slower stomach emptying keeps food in place longer, so meals feel bigger. And the appetite signal is the effect most people notice first: smaller portions, fewer cravings, less of what patients often call food noise.
The effects last while the drug is in your system. Published follow-up studies show that appetite and weight tend to move back toward baseline after treatment stops, which is why clinicians usually frame this as long-term management rather than a short course. A review of the benefits and trade-offs is available through peer-reviewed literature on PMC.
What US labeling actually approves it for
Approved uses are set product by product, not by the molecule as a whole. The daily tablet products are indicated as an addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events such as cardiovascular death, non-fatal heart attack and non-fatal stroke in adults with type 2 diabetes who are at high risk. The weekly injection carries closely related diabetes and cardiovascular indications, and some labeling has been expanded to cover kidney outcomes in adults with type 2 diabetes and chronic kidney disease. Always read the label for the specific product you are given.
A separate branded version is approved for chronic weight management alongside a reduced-calorie diet and more physical activity, in adults with obesity or with excess weight plus a weight-related health condition, and in adolescents from age 12. That product also carries a cardiovascular risk indication in certain adults, and labeling has since been widened to a liver condition known as MASH in specified patients. None of these products is approved for type 1 diabetes, and none is intended for cosmetic weight loss in people at a healthy weight.
Eligibility for the weight-management route is written in terms of body mass index plus other health conditions, so it helps to know your number before a consultation rather than during one.
BMI calculator
Most weight-loss programmes screen on BMI before they will prescribe. This is the number they will use.
A screening number, not a diagnosis. It does not distinguish muscle from fat, and it reads high for muscular builds.
On results, trials give averages, not promises. Published research on the highest weight-management dose reported average body-weight reductions in the mid-teens as a percentage over roughly 68 weeks, with wide variation between individuals, as summarised in this overview from UCLA Health on weight management. Nobody can tell you how long a specific number of pounds will take. Dose, starting weight, diet, activity, sleep, other medicines and genetics all pull on the result. Fat loss is also not targeted: the body decides where it comes from, so waist measurements usually shrink as total weight falls rather than because the drug works on the abdomen specifically. Background on medicines for overweight and obesity is available from the National Institute of Diabetes and Digestive and Kidney Diseases.
Side effects, and how long they usually last
The common problems are digestive. Nausea, vomiting, diarrhea, constipation, stomach pain, indigestion, burping, gas and reduced appetite are all frequently reported. Headache, tiredness and dizziness show up too, and injectable forms can cause redness or itching where the needle goes in. Rapid weight loss of any kind is also associated with hair shedding and loss of muscle along with fat, which is why protein intake and resistance exercise come up so often in follow-up visits.
Timing follows a pattern. Symptoms are usually strongest in the first few days after starting and again after each step up in dose, then ease over roughly one to three weeks as the body adjusts. Constipation is the exception and can grumble on for longer. Because of that pattern, treatment is normally started low and increased gradually. If nausea never settles, or it returns hard at a higher dose, that is a conversation with the prescriber rather than something to push through. A clear plain-language rundown sits with Mayo Clinic on semaglutide side effects.
Serious reactions are less common but genuinely serious. Labeling warns about acute pancreatitis, which typically presents as severe ongoing pain in the upper abdomen that may spread to the back, often with vomiting. Gallbladder problems, including gallstones, have been reported. Vomiting and diarrhea can cause dehydration severe enough to injure the kidneys. People with a history of diabetic retinopathy should be monitored, because worsening eye disease was reported in a cardiovascular outcomes trial. Severe allergic reactions can occur. There are also reports of the stomach emptying so slowly that food backs up, and of bowel obstruction.
The boxed warning and who should not take it
US labeling carries a boxed warning, the strongest warning the FDA uses. In rodent studies, this drug caused thyroid C-cell tumors in a way that depended on dose and how long treatment ran, at exposures relevant to human use. Whether it causes those tumors, including medullary thyroid carcinoma, in people is not known, because the human relevance of the rodent findings has not been determined. That uncertainty drives a hard rule rather than a soft caution.
The products are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, and in anyone with Multiple Endocrine Neoplasia syndrome type 2. They are also contraindicated in people who have had a serious allergic reaction to the active ingredient or any component of the product. Tell your clinician if you have ever had a lump or swelling in the neck, hoarseness that will not clear, trouble swallowing or persistent shortness of breath. Regulator-issued information on this drug class is collected by the US Food and Drug Administration.
Other groups need extra thought. Labeling does not support use in pregnancy, and weight loss is not advised while pregnant, so the guidance is to stop well before a planned pregnancy because the drug clears slowly. Discuss breastfeeding with a clinician. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, or an eating disorder all change the risk calculation. One more practical point: tell any surgical or anesthesia team that you take a GLP-1 before a procedure involving sedation, because delayed stomach emptying can raise the risk of stomach contents entering the lungs.
Interactions and the monitoring that goes with them
The interaction that matters most is with other diabetes medicines. Combining this drug with insulin or with insulin secretagogues such as sulfonylureas raises the risk of low blood sugar, including severe episodes. Labeling notes that the dose of the insulin or secretagogue may need to be reduced. That is a prescriber decision, not a self-adjustment, and it is a strong argument for a program that can see your full medication list rather than one that treats weight in isolation.
The second category is quieter. Slowing the stomach changes how quickly other swallowed medicines are absorbed. For most drugs this makes little practical difference, but it deserves attention with medicines that need steady levels, such as thyroid replacement or blood thinners, where extra monitoring may be sensible. The tablet form also has strict administration rules about an empty stomach, a small amount of water and a wait before eating or taking anything else. Those instructions exist because absorption is fragile; follow the label exactly rather than approximately.
Never combine two GLP-1 medicines, and be candid about supplements, over-the-counter weight products and alcohol. Alcohol can worsen nausea and, in people using insulin or sulfonylureas, low blood sugar. Reasonable monitoring usually includes A1c or glucose readings for people with diabetes, kidney function, weight, blood pressure, a review of digestive symptoms, and eye checks for anyone with existing retinopathy. Full prescribing information for every marketed product is published on DailyMed, the NIH label database.
Brands, tablets, injections and compounded copies
Semaglutide is the generic, or nonproprietary, name of the active ingredient. It is not a generic product. The brand names cover a weekly injection for type 2 diabetes and cardiovascular risk, daily tablets for type 2 diabetes and cardiovascular risk, and a separate brand for chronic weight management, which is now marketed in more than one form. So the honest answer to whether the drug and one particular brand are the same thing is: same molecule, different product, different approved uses and different dosing.
Compounded preparations are a different category again. Compounded products are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before they are sold, even though the active ingredient is the same chemical family. Compounding pharmacies fall into two broad buckets: 503A pharmacies, which prepare medicines for individual patients on a prescription, and 503B outsourcing facilities, which produce larger batches under stricter federal manufacturing oversight. Both can supply telehealth programs, and the difference is worth asking about by name.
| What differs | FDA-approved products | Compounded preparations |
|---|---|---|
| Pre-market review | Reviewed for safety, effectiveness and manufacturing quality | Not FDA-approved and not reviewed before sale |
| Active ingredient | Defined base ingredient specified in the approved label | Varies; salt forms have been flagged by the FDA as not the same ingredient |
| Strength and sterility | Manufacturer specification with batch controls | Depends on the pharmacy, its licensing and its testing |
| How it is supplied | Manufacturer device or tablet | Often vials with separate syringes, sometimes multi-dose |
| Cost basis | List price, then plan coverage or manufacturer programs | Usually bundled into a monthly self-pay program fee |
| If something goes wrong | Established recall and adverse event reporting | Depends on the pharmacy and state board oversight |
Two more cautions. The FDA has stated that some compounded versions use salt forms that are not the same active ingredient as the approved products, and that dosing errors have occurred when patients drew up their own doses. Separately, vials sold online as research chemicals or labeled not for human use are not medicines and sit outside any pharmacy chain of custody. The agency explains the legal framework in its compounding questions and answers, and pharmacy legitimacy can be checked against LegitScript certification records. If you are weighing the alternative molecule, our separate write-up on Tirzepatide And GLP-1 Alternatives covers a dual-receptor drug that works on two gut hormone pathways rather than one, and the older weekly and daily option is covered under Liraglutide Basics.
FDA-Approved Products vs. Compounded Preparations
| FDA-Approved Products | Compounded Preparations | |
|---|---|---|
| Pre-market review | Reviewed for safety, effectiveness & manufacturing quality | Not FDA-approved or reviewed before sale |
| Active ingredient | Defined base ingredient per approved label | Varies; salt forms flagged by FDA as not the same |
| Strength & sterility | Manufacturer specification with batch controls | Depends on pharmacy licensing and testing |
| Supplied as | Manufacturer device or tablet | Often vials with separate syringes |
| Cost basis | List price, plan coverage, or manufacturer programs | Usually bundled into monthly self-pay program fee |
| If something goes wrong | Established recall and adverse event reporting | Depends on pharmacy and state board oversight |
What a month costs when you are paying cash
Cash pricing is the reason most people compare programs at all. Across the self-pay programs tracked in our directory, monthly prices for this molecule run from $99 at the low end to $499 at the top, with a median of $179 across 14 tracked options. Those figures are per month, self-pay, and they move often, so treat them as a snapshot rather than a quote.
Five things move a monthly number. First, whether the prescription is for an FDA-approved brand or a compounded preparation, which is the single biggest split. Second, dose strength: many programs charge more as you titrate upward, so the cheapest first month is rarely the steady-state number. Third, whether the price includes the medicine or is only a membership or consultation fee with medication billed separately. Fourth, bundling: labs, shipping, supplies and clinician messaging may be included or added. Fifth, introductory pricing that renews higher, sometimes on a three-month or annual commitment.
Because of that, the figure worth comparing is not month one. It is what twelve months costs at the dose you expect to be on.
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
Insurance is a separate track and should never be blended with cash pricing. Some plans cover the diabetes indication but exclude weight management entirely, and prior authorization is standard for GLP-1s, with denials common rather than exceptional. Medicare rules differ again. Verify with your own plan documents before you assume anything, and ask any program directly whether it can bill your insurer or is cash only. Coverage policy trends are tracked by KFF health policy research. On the comparison side, our Free Savings Report shows how the same prescription lands at different totals, and the Free Health Calculators handle the arithmetic.
How online programs differ when they prescribe it
Programs that prescribe this drug are not interchangeable, and the differences rarely show up on the pricing page. Some run a full video consultation with a licensed clinician; others use an asynchronous questionnaire reviewed later. Some require baseline labs; others do not. Telemedicine prescribing rules and clinician licensing are set state by state, so what one program can do in your state may differ from what it does elsewhere.
The dimensions worth comparing are practical. Who reviews your intake, and can you reach them when nausea hits at week three? Is titration handled by a clinician or by a fixed schedule? Which pharmacy fills the prescription, and is it named? What happens to your price when your dose increases? How do refills work if shipping slips? Can you cancel in one click, or do you have to call? And if your insurance later approves a brand product, will the program write that prescription or only its own supply?
Our ranked breakdown of GLP-1 Telehealth Programs Compared works through those trade-offs, the Telehealth Provider Directory lists what each one offers, and How We Score Providers explains the six dimensions behind every Patient Score. Patient reviews on this site are moderated, sponsored placement is always labeled, and neither one changes a score. For related molecules and forms, the Medication Index is the fastest route, and ongoing Editorial Coverage tracks changes in the category.
Questions to ask, and symptoms that need care now
Bring a written list to the consultation. Useful questions include:
Questions to Ask Before Starting a Semaglutide Program
- Is this an FDA-approved product or a compounded preparation, and which pharmacy prepares it?
- Given my history, is there any reason I should not take a GLP-1 at all?
- How will my other medicines, especially diabetes drugs, be adjusted?
- What labs do you want before I start, and how often after that?
- How fast will the dose increase, and what do I do if side effects are bad?
- What is the total monthly cost at the dose I am likely to reach?
- How do I reach a clinician between refills, and what happens if I want to stop?
- Is this an FDA-approved product or a compounded preparation, and which pharmacy prepares it?
- Given my history, is there any reason I should not take a GLP-1 at all?
- How will my other medicines, especially any diabetes drugs, be adjusted?
- What labs do you want before I start, and how often after that?
- How fast will the dose increase, and what do I do if side effects are bad?
- What is the total monthly cost at the dose I am likely to reach?
- How do I reach a clinician between refills, and what happens if I want to stop?
Some symptoms should not wait for the next message reply. Get urgent medical care for severe or persistent stomach pain, especially if it spreads to your back or comes with repeated vomiting. Seek care for vomiting or diarrhea bad enough that you cannot keep fluids down, for signs of a severe allergic reaction such as swelling of the face, lips or throat, trouble breathing or a rapidly spreading rash, and for symptoms of severe low blood sugar such as confusion, shaking or fainting. Sudden changes in vision, and any new neck lump, hoarseness or difficulty swallowing, also warrant prompt attention.
Authoritative sources
For the primary references behind this page, see the CDC diabetes information hub for condition background. Product labeling, warnings and contraindications should always be read on the label supplied with your specific product, which is also published in the federal label database linked above. Regulatory notices about this drug class, including compounding, come directly from the FDA pages cited earlier in this guide.
Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.
